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a b s t r a c t
The empiric usage of systemic thrombolysis for refractory out of hospital cardiac arrest (OHCA) is considered for
pulmonary embolism (PE), but not for undifferentiated cardiac etiology [1, 2]. We report a case of successful resuscitation after protracted OHCA with suspected non-PE cardiac etiology, with favorable neurological outcome
after empiric administration of systemic thrombolysis.
A 47-year-old male presented to the emergency department (ED) after a witnessed OHCA with no bystander cardiopulmonary resuscitation (CPR). His initial rhythm was ventricular ﬁbrillation (VF) which had degenerated
into pulseless electrical activity (PEA) by ED arrival. Fifty-seven minutes into his arrest, we gave systemic thrombolysis which obtained return of spontaneous circulation (ROSC). He was transferred to the coronary care unit
(CCU) and underwent therapeutic hypothermia. On hospital day (HD) 4 he began following commands and
was extubated on HD 5. Subsequent percutaneous coronary intervention (PCI) revealed non-obstructive stenosis
in distal LAD. He was discharged home directly from the hospital, with one-month cerebral performance category
(CPC) score of one. He was back to work three months post-arrest.
Emergency physicians (EP) should be aware of this topic since we are front-line health care professionals for
OHCA. Thrombolytics have the advantage of being widely available in ED and therefore offer an option on a
case-by-case basis when intra-arrest PCI and ECPR are not available. This case report adds to the existing literature on systemic thrombolysis as salvage therapy for cardiac arrest from an undifferentiated cardiac etiology. The
time is now for this treatment to be reevaluated.
© 2020 Elsevier Inc. All rights reserved.

1. Case report
The American Heart Association (AHA) stated ﬁbrinolysis can be
considered for cardiac arrest secondary to suspected or conﬁrmed pulmonary embolism (PE), though not for undifferentiated refractory arrest [1,2]. Optimism for thrombolysis for OHCA from suspected acute
myocardial infarction (AMI) abruptly halted after 2008 double blinded
placebo controlled (DBPC) randomized controlled trial (RCT) reported
futility and increased intracranial hemorrhage (ICH) [3-6]. Thereafter,
the authors are not aware of further RCT in this topic.
We report a case of successful resuscitation after protracted OHCA
with suspected AMI etiology, with favorable neurological outcome
after administration of alteplase tissue plasminogen activator (tPA).
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Our objective is to explore systemic thrombolysis as a salvage therapy
for refractory OHCA despite maximal conventional resuscitative efforts.
A 47-year-old male presented to the ED after a witnessed OHCA
without bystander CPR. Emergency medical services (EMS) arrived
within 10 min and found patient in ventricular ﬁbrillation (VF). He
was deﬁbrillated seven times without ROSC; arrived at ED 29 min
later in PEA. Advanced cardiac life support continued and he was
intubated. He did have three-minute ROSC (37 min into his arrest)
where ECG revealed anterolateral AMI.
After 57 min of arrest, 50 mg of intravenous tPA was administered
and 11 min later he developed ROSC with sinus tachycardic rhythm,
for a total of 68 min downtime. Fifteen minutes later became
bradycardic and second 50 mg dose of tPA was administered.
During the remainder of ED stay he developed hypoxia and
underwent right tube thoracostomy (suspected CPR-related pneumothorax). Computed tomography (CT) head and CT angiography chest
was negative for ICH and PE, respectively. He was weaned off vasopressors in the ED.
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In CCU, he underwent therapeutic hypothermia. He remained comatose until HD four when he began to follow commands in lower extremities. The following morning, he had spontaneous eye opening and was
extubated 24 h later. He transferred out of CCU on HD 12, MRI heart on
HD 21 suggested myocarditis and cardiac catheterization on HD 22
found non-obstructing disease in the Left Anterior Descending artery.
He was discharged home from the hospital on HD 32 with no residual neurological deﬁcits and cerebral performance category (CPC) score
was one. He returned to work within three months post-arrest.
AMI and PE represent 65% of OHCA [7]. The most likely cause of this
patient's cardiac arrest was AMI, and Otani described that in witnessed
OHCA with initial shockable rhythm, greater than 50% of those are “resistant” to conventional CPR are from AMI [8]. The treatment of choice
for AMI is percutaneous coronary intervention (PCI), but infrequently
available during cardiac arrest.
Clinicians have reported positive ﬁndings utilizing thrombolysis for
OHCA in a multitude of research designs. This includes a prospective
DBPC RCT [5], before/after prospective study [3], a retrospective
propensity-matched analysis [9], a large case series [10] and case
reports as recent as 2015 [11-14]. A 2019 meta-analysis reported higher
hospital admission rates in patients given thrombolysis, though
additional outcomes for efﬁcacy and safety raised concern [15]. The authors are uncertain whether this meta-analysis' higher “survival to
admission” in thrombolytic recipients, but similar 24-h survival, could
be reﬂective of early withdrawal of life sustaining treatment (WLST)
or higher severity of illness in the thrombolytic recipients. This metaanalysis was also heavily weighted to the neg RCT in 2008, most notably
for “survival to discharge” and “bleeding complications” were weighted
66.2% and 78.9%, respectively [6]. This 2008 trial also used Tenecteplace
which is difﬁcult to directly compare to prior successful work with
Alteplase [3,4].
The probability of achieving a good outcome in cardiac arrest is optimized by a series of interventions starting at the time of arrest [16].
This case illustrates a potential workaround when prehospital care has
preserved viability and thrombolytics seem to offer little downside [4].
One intervention which gained popularity is extracorporeal membrane oxygenation (ECMO) with CPR, collectively called ECPR. Data for
ECPR for OHCA is only observational trials, and without RCT [17-19].
Our center has ECMO capability but at this time does not offer ECPR. Trials are underway to evaluate its cost-effectiveness and feasibility [20].
Also observed in this case is delayed neurological recovery after cardiac arrest, which contrasts with the fact that WLST remaining a major
cause of death of comatose OHCA patients [21]. We recognize that despite our case's CPC-1 survival, no bystander-involved protracted CPR
with late administration of systemic thrombolysis, the scale appeared
tipped towards futility.
The authors readily acknowledge the substantial limitations of the
literature on intra-arrest thrombolytics for OHCA, including publication
bias. Since the 2008 RCT, other links in the “chain of survival” have been
re-examined and the authors are uncertain if the optimization of other
links in the chain, has any effect on utility of intra-arrest ﬁbrinolysis
[22,23]. This case report builds on the existing literature on systemic
thrombolysis as salvage therapy for cardiac arrest from an undifferentiated cardiac etiology. The time is now for this treatment to be
reevaluated.
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